• Regulatory NewsRegulatory News

    FDA official discusses common deficiencies derailing ANDAs

    The US Food and Drug Administration (FDA) rejected a fewer number of abbreviated new drug applications (ANDAs) in FY 2021 through its refuse-to-receive (RTR) mechanism compared to previous years, said Peter Enos, a reviewer with the agency’s Office of Generic Drugs. He attributed the improvement to increased transparency with industry, better filing practices and enhanced communication with applicants.   Enos also addressed how industry can improve their submissions to...